BRENUS
A year ago, Brenus was selected to participate in CDL Cancer, a global mentorship program for massively scalable, science-based and innovative companies accelerating cancer treatment.
Thanks to its pioneering STC platform, dedicated to developing a new generation of therapeutic cancer vaccines, Brenus stood out during a scientific evaluation with Dr. John Bell (Principal Senior Scientist at Ottawa Hospital Cancer Research Institute & Professor of Medicine & Immunology at University of Ottawa).
Brenus has graduated from the program along with 9 other companies, successfully completing the 4 sessions that took place from October 2023 to June 2024 across North America.
In this program, Brenus came to seek strategic, international guidance for the development of its platform and their lead candidate targeting colorectal cancer.
During each session, the objectives and updates presented were challenged by the CDL community and mentors: successful entrepreneurs, investors, corporate partners, KOLs, and more, all coming from prestigious institutions (University of New York, Oxford, Toronto, British Columbia). The support received was instrumental in validating Brenus Pharma’s roadmap and accelerating the achievement of strategic milestones in R&D (multi-omics and AI), finance and partnerships.
“The CDL sessions, based on an interesting “creative destruction” method, allowed us to leverage expertise across the CDL community and anticipate the next key steps to bring our innovation to patients with urgent unmet needs. This year has already been rich in achievements for Brenus, and we will continue to drive operational excellence to bring our company further. We are proud to have up taken the CDL challenge and we thank our mentors for their trust.” said Paul Bravetti, CEO of Brenus Pharma.
About CDL Cancer
This unique CDL-Global stream brings together global leaders and experts across the cancer care continuum to support technology innovations that improve the cancer experience globally, from prevention to diagnosis, treatment, and survivorship.
About the Creative Destruction Lab
The Creative Destruction Lab (CDL) is a program for massively scalable, science-based companies. The nine-month program employs an objectives-based mentoring process with the goal of maximizing equity-value creation. The CDL is particularly suited to early stage companies with links to university research labs. Launched in 2012 at the Rotman School of Management at the University of Toronto, the program has now expanded with locations in Vancouver, Calgary, Montreal, Halifax, and New York City.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627958275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TEVA-PHARMACEUTICAL28.6.2024 17:31:27 CEST | Press release
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
YARD-FORCE28.6.2024 08:08:27 CEST | Press release
Yard Force Introduces the 21W Portable Solar Charger with Dual USB Ports and 13000 mAh Built-in Battery
AQEMIA28.6.2024 07:31:26 CEST | Press release
AQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier
YARD-FORCE28.6.2024 06:13:34 CEST | Press release
Yard Force Launches the LX PS300 Portable Power Station - Your Ultimate Mobile Power Solution
YARD-FORCE28.6.2024 06:01:33 CEST | Press release
Yard Force Introduces the 100W Portable Solar Panel LX SPP10 - Your Ideal Solar Charging Solution
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom